• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States

    9/30/25 8:00:00 AM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $LENZ alert in real time by email

    VIZZ sample distribution initiated nationwide to Eye Care Professionals

    Commercial product shipments to be initiated in October to consumers with broad product availability by mid-Q4 2025

    VIZZ is the first and only aceclidine-based eye drop approved to improve near vision in adults with presbyopia for up to 10 hours, a condition impacting approximately 128 million adults in the United States

    SAN DIEGO, Sept. 30, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), today announced VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, is now available. Professional product sample distribution by the sales force to optometrists and ophthalmologists has been initiated nationwide. Commercial product shipments will be initiated to consumers in October through our ePharmacy partner and is anticipated to be broadly available, including via retail pharmacies, by mid-Q4 2025.

    "We are thrilled to introduce VIZZ to the 128 million adults living with blurry near vision in the United States," said Eef Schimmelpennink, President and Chief Executive Officer of LENZ Therapeutics. "The team has been preparing for this moment for months and worked tirelessly to enable the availability of product samples and commercial product following our FDA approval. Initial feedback and early brand awareness from the ECP community is extremely positive, and we feel well-positioned for a successful product launch, firmly establishing VIZZ as a Category of One for the treatment of presbyopia."

    VIZZ is powered by aceclidine, differentiated by its mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation. VIZZ contracts the iris sphincter muscle, resulting in a pinhole effect and uniquely achieves a sub-2mm pupil that extends depth of focus to significantly improve near vision without causing a myopic shift. In the CLARITY Phase 3 clinical trial, 93% of participants achieved 20/40 or better near vision within 30 minutes and lasted up to 10 hours. This level of near vision can restore the ability to read a phone screen and other everyday fine print without the assistance of reading glasses.

    "With VIZZ now available, we're giving people living with presbyopia a simple, fast-acting way to see up close again," said Shawn Olsson, Chief Commercial Officer of LENZ Therapeutics. "It's about restoring everyday confidence, including reading a phone, checking a price tag, or enjoying your active lifestyle glasses-free. We're excited to bring this new option to millions who want more freedom in their near vision."

    For more information about VIZZ and full prescribing information, please visit www.VIZZ.com.

    About Presbyopia

    Presbyopia is the inevitable loss of near vision associated with aging. It impacts the daily lives of nearly all people over the age of 45. As people age, the crystalline lens in their eyes gradually hardens and becomes less able to change shape. This loss of elasticity of the lens reduces the ability of the lens to focus incoming light from near objects onto the retina. Adults over age 50 lose, on average, 1.5 lines of near vision every six years. Although the progression of presbyopia is gradual, presbyopes often experience an abrupt change in their daily life as the symptoms become more pronounced starting in their mid-40s, when reading glasses or other corrective aids are suddenly necessary to read text or conduct close-up work. Presbyopia is typically self-diagnosed and self-managed with over-the-counter reading glasses, or managed, after evaluation by an ECP, with prescription reading or bifocal glasses or multifocal contact lenses.

    About VIZZ (aceclidine ophthalmic solution) 1.44%

    VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. Aceclidine is the sole active ingredient in VIZZ and provides rapid and durable near vision improvement. VIZZ is preservative-free and provided in single-dose vials. VIZZ is a predominantly pupil selective miotic that interacts with the iris with minimal ciliary muscle stimulation. VIZZ causes contraction of the iris sphincter muscle, resulting in a pinhole effect that extends depth of focus to improve vision.

    VIZZ Indication and Important Safety Information

    INDICATION

    VIZZ (aceclidine ophthalmic solution) 1.44% is a prescription eye drop used to treat age-related blurry near vision (presbyopia) in adults.

    IMPORTANT SAFETY INFORMATION

    • Do not use VIZZ if allergic to any of the ingredients.
    • To help avoid potential eye injury or contamination of the product, do not allow the vial tip to touch the eye or any surfaces. Discard the opened vial immediately after use.
    • Contact lenses should be removed before using VIZZ. After dosing, contact lenses can be reinserted after 10 minutes.
    • If using more than one topical eye medication, the medicines should be administered at least 5 minutes apart.
    • Temporary dim or dark vision may be experienced after using VIZZ. Do not drive or operate machinery if vision is not clear.
    • Seek immediate medical care if sudden onset of flashing lights, floaters, or vision loss is experienced.

    ADVERSE REACTIONS

    The most common reported adverse reactions of participants were instillation site irritation (20%), dim vision (16%), and headache (13%). Adverse reactions reported in >5% of participants were conjunctival hyperemia (8%) and ocular hyperemia (7%). The majority of adverse reactions were mild, transient, and self-resolving.

    For additional information, please see the full Prescribing Information available at www.VIZZ.com.

    About LENZ Therapeutics

    LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZ™ (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. LENZ is commercializing VIZZ in the United States and continues to establish licensing partnerships internationally to provide access to VIZZ globally. LENZ is headquartered in San Diego, California. For more information, visit: LENZ-Tx.com. 

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of federal securities laws. You can identify forward-looking statements by words such as "may," "will," "could," "can," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "poised," "continue," "ongoing" or the negative of these terms or other comparable terminology, but not all forward-looking statements will contain these words. " Forward-looking statements in this press release include statements regarding the timing and availability of VIZZ; potential market size for VIZZ; its ability to meet patient needs and become standard of care; LENZ commercialization plans, including international partnering plans, and the quotations of LENZ management. These statements are based on numerous assumptions concerning VIZZ, target markets and involve substantial risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievement to be materially different from the information expressed or implied by these forward-looking statements, including those risk factors described in the section titled "Risk Factors" in our Quarterly Report on Form 10-Q filed for the quarter ended June 30, 2025 and our subsequent filings with the SEC. We cannot assure you that the forward-looking statements in this press release or the assumptions upon which they are based will prove to be accurate. The forward-looking statements in this press release are as of the date of this press release. Except as otherwise required by applicable law, LENZ disclaims any duty to update any forward-looking statements. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. 

    Contact:

    Dan Chevallard

    LENZ Therapeutics

    [email protected]



    Primary Logo

    Get the next $LENZ alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LENZ

    DatePrice TargetRatingAnalyst
    4/14/2025$38.00 → $51.00Overweight
    Piper Sandler
    3/18/2025$60.00Buy
    TD Cowen
    9/27/2024$37.00Outperform
    Raymond James
    8/12/2024$38.00Buy
    H.C. Wainwright
    4/15/2024Outperform
    William Blair
    4/15/2024$32.00Outperform
    Leerink Partners
    4/10/2024$34.00Buy
    Citigroup
    3/27/2024$28.00Overweight
    Piper Sandler
    More analyst ratings

    $LENZ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler resumed coverage on LENZ Therapeutics with a new price target

    Piper Sandler resumed coverage of LENZ Therapeutics with a rating of Overweight and set a new price target of $51.00 from $38.00 previously

    4/14/25 8:17:08 AM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    TD Cowen initiated coverage on LENZ Therapeutics with a new price target

    TD Cowen initiated coverage of LENZ Therapeutics with a rating of Buy and set a new price target of $60.00

    3/18/25 7:53:26 AM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Raymond James initiated coverage on LENZ Therapeutics with a new price target

    Raymond James initiated coverage of LENZ Therapeutics with a rating of Outperform and set a new price target of $37.00

    9/27/24 7:38:17 AM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LENZ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States

    VIZZ sample distribution initiated nationwide to Eye Care Professionals Commercial product shipments to be initiated in October to consumers with broad product availability by mid-Q4 2025 VIZZ is the first and only aceclidine-based eye drop approved to improve near vision in adults with presbyopia for up to 10 hours, a condition impacting approximately 128 million adults in the United States SAN DIEGO, Calif., Sept. 30, 2025 /PRNewswire/ -- LENZ Therapeutics, Inc. (NASDAQ:LENZ, LENZ", or the ", Company", )), today announced VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, is now available. Profes

    9/30/25 8:05:00 AM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States

    VIZZ sample distribution initiated nationwide to Eye Care Professionals Commercial product shipments to be initiated in October to consumers with broad product availability by mid-Q4 2025 VIZZ is the first and only aceclidine-based eye drop approved to improve near vision in adults with presbyopia for up to 10 hours, a condition impacting approximately 128 million adults in the United States SAN DIEGO, Sept. 30, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), today announced VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, is now available. Professional product sample d

    9/30/25 8:00:00 AM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    LENZ Therapeutics to Present at Upcoming Investor and Medical Conferences

    SAN DIEGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pharmaceutical company focused on the commercialization of VIZZ™ (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that company management will participate in the following upcoming investor and medical conferences, including presentations featuring VIZZ at Academy 2025 presented by the American Academy of Optometry. Citi's 2025 BioPharma Back to School ConferenceDate: September 2-3, 2025Location: Boston, MAFormat: Fireside chat at 9:45am EDT (live audio webcast) and 1x1 investor meetings C

    8/25/25 8:00:00 AM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LENZ
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chevallard Daniel R. bought $49,988 worth of shares (3,188 units at $15.68) (SEC Form 4)

    4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

    5/15/24 4:13:06 PM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LENZ
    SEC Filings

    View All

    LENZ Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - LENZ Therapeutics, Inc. (0001815776) (Filer)

    9/30/25 8:06:43 AM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by LENZ Therapeutics Inc.

    SCHEDULE 13D/A - LENZ Therapeutics, Inc. (0001815776) (Subject)

    9/22/25 4:20:58 PM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by LENZ Therapeutics Inc.

    SCHEDULE 13D/A - LENZ Therapeutics, Inc. (0001815776) (Subject)

    8/20/25 5:13:51 PM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LENZ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Versant Venture Capital Vi, L.P. sold $5,714,356 worth of shares (135,304 units at $42.23) (SEC Form 4)

    4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

    9/22/25 4:23:19 PM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Versant Venture Capital Vi, L.P. sold $7,423,920 worth of shares (188,094 units at $39.47) (SEC Form 4)

    4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

    8/26/25 7:59:49 PM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Versant Venture Capital Vi, L.P. sold $10,255,244 worth of shares (260,713 units at $39.34) (SEC Form 4)

    4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

    8/19/25 4:51:33 PM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LENZ
    Leadership Updates

    Live Leadership Updates

    View All

    Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

    WELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors. Ms. Drapkin will assume the role of Audit Committee Chair, and Mr. Cumbo will assume the role of Compensation Committee Chair. "We are delighted to welcome Kim and Bo to our Board of Directors at Climb Bio," said Aoife Brennan, President and CEO of Climb Bio. "Kim and Bo each bring three decades of leadership experience in the biotechnology and pharmaceutical industry, offering invaluable perspective as we continue to build the company and advance our pipeline. Their insight

    4/1/25 7:00:00 AM ET
    $ABOS
    $CLYM
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Lucy Therapeutics Appoints Kim Drapkin as Board Chair

    Drapkin brings decades of biotech and pharma experience as the company prepares for clinical trial development. Lucy Therapeutics, Inc. (LucyTx), a biotech company developing proprietary small molecule therapies for complex neurological diseases including Rett syndrome, Parkinson's and Alzheimer's, today announced the appointment of Kim Drapkin as Board Chair. She will help guide the strategic direction of LucyTx as the company enters its next phase of growth: clinical trial development. "It's an honor to lead LucyTx's Board. The company's non-traditional approach to developing treatments for complex diseases is already paying off, and I'm eager to contribute to both their clinical and st

    10/15/24 8:00:00 AM ET
    $ABOS
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    LENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024

    Capstone data from Phase 3 CLARITY study to be presented Event to feature Key Opinion Leader and Principal Investigator perspectives on LNZ100 potential in presbyopia SAN DIEGO, June 10, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that the Company will host a Key Opinion Leader ("KOL") event on Tuesday, June 18, 2024 at 8:00 a.m. ET. The event will highlight real-world insights by Key Opinion Leaders and Principal Investigators on the current treatment landscape for presbyopia and their perspectiv

    6/10/24 8:00:00 AM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LENZ
    Financials

    Live finance-specific insights

    View All

    LENZ Therapeutics Announces US FDA Approval of VIZZ™ for the Treatment of Presbyopia

    VIZZ is the first and only aceclidine-based eye drop approved to improve near vision in adults with presbyopia, a condition impacting approximately 128 million adults in the United States First once daily solution to treat blurry near vision with proven efficacy for up to 10 hours VIZZ samples and product availability in the United States expected as early as October 2025 Conference call and webcast to be held August 1, 2025 at 8:00 a.m. EDT  SAN DIEGO, July 31, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), today announced the US Food and Drug Administration ("FDA") approved VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based

    7/31/25 4:05:00 PM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    LENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

    New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025 Cash, cash equivalents and marketable securities of $194.1 million as of March 31, 2025 Upwardly revised anticipated cash balance at PDUFA to over $185.0 million; cash runway anticipated to extend to post-launch positive operating cash flow Company to host a conference call today at 4:30 p.m. EDT SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presby

    5/7/25 4:05:00 PM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    LENZ Therapeutics to Report First Quarter 2025 Financial Results and Recent Corporate Highlights on May 7th, 2025

    SAN DIEGO, April 30, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced it will host a webcast on Wednesday, May 7th, 2025, at 4:30 p.m. EDT to report its first quarter 2025 financial results and recent corporate highlights. To participate in the conference call via telephone, dial (800) 715-9871 (Domestic) or (646) 307-1963 (International) and enter code 8251197. The live webcast can be accessed here and on the LENZ Therapeutics website at www.LENZ-tx.com in the Inve

    4/30/25 4:30:00 PM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LENZ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by LENZ Therapeutics Inc.

    SC 13G/A - LENZ Therapeutics, Inc. (0001815776) (Subject)

    11/14/24 4:00:05 PM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by LENZ Therapeutics Inc.

    SC 13D/A - LENZ Therapeutics, Inc. (0001815776) (Subject)

    11/8/24 5:08:56 PM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by LENZ Therapeutics Inc.

    SC 13G - LENZ Therapeutics, Inc. (0001815776) (Subject)

    7/29/24 4:12:50 PM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care